

Substituted tetrahydroquinolines

BACKGROUND OF THE INVENTION

The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

The present invention relates to compounds of the formula I and to the use thereof for the treatment and prophylaxis of diseases in which the inhibition, regulation and/or modulation of mitotic motor proteins, in particular the mitotic motor protein Eg5, plays a role, furthermore to pharmaceutical compositions which comprise these compounds.

In detail, the present invention relates to compounds of the formula I which preferably inhibit, regulate and/or modulate one or more mitotic motor proteins, to compositions which comprise these compounds, and to methods for the use thereof for the treatment of diseases and complaints such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, choroidal neovascularisation and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or transplant rejection. In particular, the compounds according to the invention are suitable for the therapy or prophylaxis of cancer diseases.

During mitosis, various kinesins regulate the formation and dynamics of the spindle apparatus, which is responsible for correct and coordinated alignment and separation of the chromosomes. It has been observed that specific inhibition of a mitotic motor protein – Eg5 – results in collapse of the spindle fibres. The result of this is that the chromosomes can no longer be distributed correctly over the daughter cells. This results in mitotic arrest

and can consequently cause cell death. Upregulation of the motor protein Eg5 has been described, for example, in tissue from breast lung and colon tumours. Since Eg5 takes on a mitosis-specific function, it is principally rapidly dividing cells and not fully differentiated cells that are affected by Eg5 inhibition. In addition, Eg5 regulates exclusively the movement of mitotic microtubuli (spindle apparatus) and not that of the cytoskeleton. This is crucial for the side-effect profile of the compounds according to the invention since, for example, neuropathies, as observed in the case of Taxol, do not occur or only do so to a weakened extent. The inhibition of Eg5 by the compounds according to the invention is therefore a relevant therapy concept for the treatment of malignant tumours.

In general, all solid and non-solid tumours can be treated with the compounds of the formula I, such as, for example, monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, including lung adenocarcinoma and small-cell lung carcinoma. Further examples include prostate, pancreatic and breast carcinoma.

Surprisingly, it has been found that the compounds according to the invention effect specific inhibition of mitotic motor proteins, in particular Eg5.

The compounds according to the invention preferably exhibit an advantageous biological activity which can easily be detected in the assays described herein, for example. In such assays, the compounds according to the invention preferably exhibit and cause an inhibiting effect, which can usually be documented by IC_{50} values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range.

As discussed herein, effects of the compound according to the invention are relevant to various diseases. Accordingly, the compounds according to the invention are useful in the prophylaxis and/or treatment of diseases which are influenced by inhibition of one or more mitotic motor proteins, in particular Eg5.

The present invention therefore relates to compounds according to the invention as medicaments and/or medicament active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the said diseases, and also to a method for the treatment of the said diseases comprising the administration of one or more compounds according to the invention to a patient in need of such an administration.

It can be shown that the compounds according to the invention have an advantageous effect in a xenotransplant tumour model.

The host or patient can belong to any mammal species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cattle, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for the treatment of a human disease.


The susceptibility of a certain cell to treatment with the compounds according to the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound according to the invention at various concentrations for a period of time which is sufficient to enable the active ingredients to inhibit cell proliferation or induce cell death, usually between approximately one hour and one week. For testing in vitro, cultivated cells from a biopsy sample or established cell lines can be used. The viable cells remaining after the treatment are then counted.

The dose varies depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose is sufficient considerably to reduce the undesired cell population in the target tissue, while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example at least

about a 50% reduction in the cell burden, and can be continued until essentially no undesired cells are detected in the body.

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula I



in which

W denotes CH or N,

R^1 , R^2 , R^3 , independently of one another, denote H, A, aryl, heteroaryl, Hal, $-(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, R, NR-NR₂, X(CY₂)_nXR, X(CY₂)_nY, (CY₂)_n-cycloalkyl, (CY₂)_nCH=CH₂, cycloalkyl, -SCH₃, -SCN, -CF₃, -OCF₃, -OA, $-(CY_2)_n-OH$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$, $-(CY_2)_n-Hal$, $-(CY_2)_n-Y$, $-(CY_2)_nR^a$, $-(CY_2)_n-NR_2$, (CY₂)_n-OA, (CY₂)_n-OCOA, -SCF₃, (CY₂)_n-CONR₂, $-(CY_2)_n-NHCOA$, $-(CY_2)_n-NHSO_2A$, SF₅, Si(CH₃)₃, CO-(CY₂)_n-CH₃, $-(CY_2)_n-N$ -pyrrolidone, (CH₂)_nNRCOOR, NRCOOR, NCO, (CH₂)_nCOOR, NCOOR, (CH₂)_nOH, NR(CH₂)_nNR₂, C(OH)R₂, NR(CH₂)_nOR, NCOR, (CH₂)_n-aryl, (CH₂)_n-heteroaryl, (CH₂)_nR¹, (CH₂)_nX(CH₂)_n-aryl, (CH₂)_nX(CH₂)_n-heteroaryl, (CH₂)_nCONR₂, XCONR(CH₂)_nNR₂, N[(CH₂)_nXCOOR]CO(CH₂)_n-aryl, N[(CH₂)_nXR]CO(CH₂)_n-aryl, N[(CH₂)_nXR]CO(CH₂)_n-X-aryl, N[(CH₂)_nXR]SO₂(CH₂)_n-aryl,

$N[(CH_2)_nNR_2]CO(CH_2)_n\text{-aryl}$,
 $N[(CH_2)_nNR_2]CO(CH_2)_n\text{-aryl}$, $N[(CH_2)_nNR_2]CO(CH_2)_nNR\text{-aryl}$,
 $N[(CH_2)_nNR_2]SO_2(CH_2)_n\text{-aryl}$, $N[(CH_2)_nXR]CO(CH_2)_n\text{-hetero-}$
 aryl , $N[(CH_2)_nXR]CO(CH_2)_nX\text{-heteroaryl}$, $CO\text{-aryl}$, $SO_2\text{-aryl}$,
 $N[(CH_2)_nXR]SO_2(CH_2)_n\text{-heteroaryl}$,
 $N[(CH_2)_nNR_2]CO(CH_2)_n\text{-heteroaryl}$,
 $N[(CH_2)_nNR_2]CO(CH_2)_nNR\text{-heteroaryl}$, R^1 and R^3 together
 also denote $-N-C(CF_3)=N-$, $-N-CR=N-$, $-N=N=N-$ and where
 non-adjacent CY_2 groups may also be replaced by X

Y denotes H, A, Hal, OR, $E-R^1$,

E denotes $-NR^1SO_2-$, $-SO_2NR^1-$, $-CONR^1-$, $-NR^1CO-$, $-COO-$,
 $OOC-$, CO , $-SO_2-$, $-X-$, NR^1CONR^1- , $-OCONR^1-$, $-NR^1COO-$,
 $-CSNR^1-$, $-NR^1CS-$, $-NR^1CSNR^1-$, $-SCONR^1-$, $-NR^1COS-$,
 $-OCSNR^1-$, NR^1CSO- , $SCSNR^1-$, $-NR^1CSS$ or a single bond

A denotes alkyl or cycloalkyl, in which one or more H atoms may be replaced by Hal,

Hal denotes F, Cl, Br or I

R denotes H or A, in the case of geminal radicals R together
 also $-(CH_2)_5-$, $-(CH_2)_4-$ or $-(CH_2)_nX-(CH_2)_n$, or
 $-(CH_2)_nZ-(CH_2)_n$,

$R^4, R^{4'}$,







$R^5, R^{5'}$,


independently of one another, denote H or unsubstituted or
 mono- or poly-OR-, $-NO_2-$, $-Hal-$, $-CF_3-$, $-OCF_3-$, $-CN-$, $-NR_2-$
 or $-SR-$, $-aryl-$ or $-heteroaryl-$ -substituted N-pyrrolidone, Q,

$-(\text{CY}_2)_n\text{-E-CR}_2\text{R}^1$, $-(\text{CY}_2)_n\text{-E-CR}_2\text{XR}^1$, $-(\text{CY}_2)_n\text{-E-(CY}_2)_n\text{XR}^1$ or
 $-(\text{CY}_2)_n\text{-E-(CY}_2)_n\text{-XR}^a$, $-\text{X-(CH}_2)_2\text{OR}$, $-\text{X-CO(CH}_2)_n\text{CH}_3$,
 $-\text{X-(CH}_2)_2\text{NR}_2$, R^1 , S-aryl, O-aryl, $\text{CH}_2\text{Si(CH}_3)_3$, or together
denote $-\text{X(CR}_2)_2-$, $-\text{X(CR}_2)_3-$, $-\text{XCHQCY}_2-$,
 $-\text{X-CH(CH}_2\text{OR)(CY}_2)_2-$, $-\text{X-CH(CH}_2\text{NR}_2)(\text{CY}_2)_2-$,
 $-\text{X-CH=CQ-CH}_2-$, X-CQ=CH-CH_2- , $-\text{X(CH}_2)_2\text{NR}_2$, $-(\text{CR}_2)_3-$,
 $-(\text{CR}_2)_4-$, $-\text{CR=CR-CR=CR-}$, $-\text{XCHQ(CY}_2)_2-$, $-\text{XCHQCR}_2-$,
 R-N-(C=X)-N-R , $-\text{XC}[(\text{CH}_2)_n\text{OR}]_2\text{-CH}_2\text{CH}_2-$,
 $-\text{X-CY}_2\text{CH(CH}_2\text{OR)CY}_2-$, $-\text{X-CY}_2\text{CH(CH}_2\text{NR}_2)\text{CY}_2-$,
 $-\text{X-CY}_2\text{CHQ-CY}_2-$, $-\text{XCHQCY}_2-$, $-\text{XCY}_2\text{CHQ-}$, $-\text{XCHQ(CY}_2)_3-$,
 $-\text{XCHQ(CY}_2)_4-$, $-\text{XCY}_2\text{CHQ(CY}_2)_2-$, $-\text{XCY}_2\text{CHQ(CY}_2)_3-$,


15 X denotes O, S or NR¹,

Q denotes $(\text{CH}_2)_p\text{-E-(CH}_2)_p\text{R}^1$, $(\text{CH}_2)_p\text{-E-(CH}_2)_p\text{R}^a$, $(\text{CH}_2)_p\text{Hal}$,
 CHO , $(\text{CH}_2)_p\text{SR}^1$, COR^a , $(\text{CH}_2)_p\text{R}^a$, $(\text{CH}_2)_p\text{OCOR}^a$,
 $(\text{CH}_2)_p\text{NCOR}^1$, $(\text{CH}_2)_p\text{N(R}^1)_2$, $(\text{CH}_2)_p\text{OR}^1$, $(\text{CH}_2)_p\text{OCON(R}^1)_2$,
 $(\text{CH}_2)_p\text{OCOOR}^1$, $(\text{CH}_2)_p\text{NHCON(R}^1)_2$, $(\text{CH}_2)_p\text{NHCOOR}^1$,
 $(\text{CH}_2)_p\text{CN}$, $(\text{CH}_2)_p\text{COOR}^1$


 R^a denotes




5




10




15




20





25




30



35




5




10


15




20




25



30



35



OR, NHR, NR₂, NR(CH₂)_n-aryl, NR(CH₂)_nOR, COOR,
 N-pyrrolidone radical, OCOR, NR(CH₂)_nNR₂, (CY₂)_n-aryl,
 (CY₂)₂-heteroaryl, N[(CH₂)_nNR₂]CO(CH₂)_n-aryl, N[(CH₂)_n-
 5 NHCOOR]CO-aryl, R¹, N[CH₂(CH₂)_nOR]₂, NR(CH₂)_nNCOOR,
 X(CH₂)_nX(CH₂)_nXR, NR(CH₂)_nX(CH₂)_nOH, NR(CH₂)_nO(CH₂)_n-
 OH, (CH₂)_nCOOR, O(CO)NR(CH₂)_nOR, O(CO)(CH₂)_nNR₂,
 NR(CH₂)_nNR₂, N[(CH₂)_nNR₂]CO(CH₂)_n-aryl, N[(CH₂)_nXR]-
 10 CO(CH₂)_n-aryl, N[(CH₂)_nXR]CO(CH₂)_n-heteroaryl,
 N[(CH₂)_nNR₂]CO(CH₂)_n-heteroaryl, N[(CH₂)_nNR₂]CO(CH₂)_nR¹,
 N(R)(CH₂)_nN(R)COOR, XCOO(CH₂)_nNR₂, OSO₂A, OSO₂CF₃,
 OSO₂Ar, OCONR₂, OCH₂(CH₂)_nNR₂, CONR¹, COR¹,

15 Z denotes CH₂, X, CHCONH₂, CH(CH₂)_nNR¹COOR¹,
 CHNR¹COOR¹, NCHO, CHCON(R¹)₂, CH(CH₂)_nCOOR¹,
 NCOOR¹, CH(CH₂)_nOH, N(CH₂)_nOH, CHNH₂, CH(CH₂)_nNR¹₂,
 CH(CH₂)_nNR¹₂, C(OH)R¹, CHNCOR¹, NCOR¹, N(CH₂)_n-aryl,
 20 N(CH₂)_n-heteroaryl, CHR¹, NR¹, CH(CH₂)_n-aryl, CH(CH₂)_n-
 heteroaryl, CH(CH₂)_nR¹, N(CH₂)_nCOOR¹, CH(CH₂)_nX(CH₂)_n-
 aryl, CH(CH₂)_nX(CH₂)_n-heteroaryl, NSO₂R, N(CH₂)_nCON(R¹)₂,
 NSO₂R¹, CHSO₂N(R¹)₂, XCONR(CH₂)_nN(R¹)₂, NCO(CH₂)_n-
 25 aryl, NCO(CH₂)_nX-aryl, NSO₂(CH₂)_n-aryl, NCO(CH₂)_n-aryl,
 NCO(CH₂)_nNR¹-aryl, NCO(CH₂)_n-heteroaryl, NCO(CH₂)_nX-
 heteroaryl, NSO₂(CH₂)_n-heteroaryl,
 NCO(CH₂)_nNR¹-heteroaryl, N(CH₂)_nNR₂CH,
 30 CHO(CH₂)_nN(R¹)₂, CHX(CH₂)_nN(R¹)₂, NCO(CH₂)_nNR₂, CHR^a,
 NR^a, C(OH)CY₃, C(OH)-aryl, C(NR₂)-aryl,

R⁶ denotes aryl or heteroaryl, each of which is unsubstituted or
 mono- or polysubstituted by aryl or heteroaryl (which may be
 35 substituted by Hal, NO₂, CN, A, OR, OCOR, COR, NR₂, CF₃,
 OCF₃, OCH(CF₃)₂), or by Hal, NO₂, CN, OR, A, -(CY₂)_n-OR,

-OCOR, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$, -NCOR, -COR or
 $-(CY_2)_n-NR_2$,

5 $R^{6'}$ denotes H or R^6

R^7 denotes (C=O)-R, (C=O)- NR_2 , (C=O)-OR, H or A

10 m denotes 0, 1 or 2

and

n denotes 0, 1, 2, 3, 4, 5, 6 or 7

15 p denotes 0, 1, 2, 3, 4, or 5, preferably 1 or 2

S denotes 0, 1, 2, 3 or 4, in particular 0

20 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25 The invention also relates to the optically active forms, the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term solvates of the compounds is taken to mean adducts of inert solvent molecules onto the compounds of the formula I which form owing to their mutual attractive force. solvates are, for example,
30 mono- or dihydrates or alkoxides.

Pharmaceutically usable derivatives are taken to mean, for example, the salts of the compounds according to the invention and also so-called
35 prodrug compounds.

Prodrug derivatives are taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars

or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention.

These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm.

115, 61-67 (1995).

Similar compounds are described, for example, in Tetrahedron Lett. **1988**, 29, 5855-5858, Tetrahedron Lett. **2003**, 44, 217-219, J. Org. Chem. **1997**, 62, 4880-4882, J. Org. Chem. **1999**, 64, 6462-6467, Chem. Lett. **1995**, 423-424, J. Org. Chem. **2000**, 65, 5009-5013, Chem. Lett. **2003**, 32, 222-223, US2003149069A1, but are not mentioned in connection with cancer treatments and/or do not contain the features essential to the invention.

The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

In addition, the expression "therapeutically effective amount" denotes an amount which causes at least one of the following effects in a human or another mammal (compared with a subject who has not received this amount):


improvement in the healing treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side-effects or also the reduction in the progress of a disease, condition or disorder.

The term "therapeutically effective amount" also encompasses the amounts which are effective for increasing or enhancing normal physiological function.

The invention also relates to the use of mixtures of the compounds according to the invention, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.


These are particularly preferably mixtures of stereoisomeric compounds.

The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I according to the patent claims and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that a compound of the formula II



in which R^1 , R^2 and R^3 have the meanings indicated above,

is reacted with a compound of the formula III




in which

R^6 and s have the meanings indicated above,

and

with a compound of the formula IV, the double-bond isomer (E isomer) thereof or mixtures thereof



in which R^4 , $R^{4'}$, R^5 and $R^{5'}$ have the meanings indicated above,
preferably in the presence of a protonic acid or Lewis acid, such as, for
example, trifluoroacetic acid, hexafluoroisopropanol, bismuth(III) chloride,
ytterbium(III) triflate, scandium(III) triflate or cerium(IV) ammonium nitrate,


and a radical other than H is optionally introduced by conventional methods for R^7 .

The mixtures of diastereomers and enantiomers of the compounds of the formula I which may be obtained by the process described above are preferably separated by chromatography or crystallisation.

If desired, the bases and acids of the formula I obtained by the process described above are converted into their salts.

In particular, the compounds according to the invention can be prepared analogously to the following schemes, where, in particular, the radical Q takes place by modification of an existing radical by known methods:

Scheme 1




[1] H.K. Hall, L.J. Carr, R. Kellman, F. de Blauwe, J. Am. Chem. Soc. 1974, 96, 7265-7269.

[2] M. Okada, H. Sumitomo, M. Atsumi, H.K. Hall, R.B. Ortega, Macromolecules 1986, 19, 503-509.

[3] M. Okada, H. Sumitomo, T. Sassa, M. Takai, H.K. Hall, M. Bruck, Macromolecules 1990, 23, 2427-.


Scheme 2



[1] Bruckner et al., Acta Chim. Acad. Sci. Hung. 1959, 21, 105, 116.

[2] Y. Suhara, F. Sasaki, G. Koyama, K. Maeda, H. Umezawa, M. Ohno, J. Am. Chem. Soc. 1972, 94, 6501-6507


Scheme 3



[1] e.g. Synthesis described in E.R.H. Jones, J.S. Stehpenon, W.B. Turner, M.C. Whiting, J. Chem. Soc. 1963, 2048-2055.

[2] F.E. McDonald, C.B. Connolly, M.M. Gleason, T.B. Towne, K.D. Treiber, J. Org. Chem. 1993, 58, 6952-6953.

Scheme 4




[1] M.R. Lamborg, R.M. Burton, N.O. Kaplan, J. Am. Chem. Soc. 1957, 79, 6173-6177.

[2] P. Karrer, F. Blumer, Helv. Chim. Acta 1947, 30, 1157.


[3] I. Carranco, J.L. Diaz, O. Jimenez, M. Vendrell, F. Albericio, M. Royo, R. Lavilla, J. Comb. Chem. 2005, 7, 33-41.

Scheme 5



- [1] B. Fraser-reid, B. Radatus, J. Am. Chem. Soc. 1970, 92, 6661-6663.
[2] N. Greenspoon, E. Keinan, J. Org. Chem. 1988, 53, 3723-3731.

Scheme 6



15 Above and below, the radicals R , R^1 , R^2 , R^3 , R^4 , R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , X , Y , E , Q , R^a , Z , W , m , n , p and S have the meanings indicated for the formula I, unless expressly indicated otherwise. If individual radicals occur a number of times within a compound, the radicals adopt the meanings indicated, independently of one another.

25 If individual indices occur more than once within a compound or radical, the indices preferably, independently of one another, adopt the meanings indicated, unless expressly indicated otherwise. Thus, for example, the indices p in the radicals Q in which they occur more than once are preferably in each case selected, independently of one another, from the meanings indicated above and/or below, unless expressly indicated otherwise.

30 A denotes alkyl, is preferably unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-

35

2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl. A also denotes cycloalkyl.

Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, but in particular cyclopentyl.

E is preferably $-\text{NR}^1\text{SO}_2-$, $-\text{SO}_2\text{NR}^1-$, $-\text{CONR}^1-$, $-\text{NR}^1\text{CO}-$, $-\text{NR}^1-\text{CO}-\text{NR}^1-$ or $-\text{OCONR}^1-$. E is particularly preferably $-\text{NR}^1\text{CONR}^1-$.


R^1 preferably denotes A, CF_3 , OCF_3 , SA, SCN, CH_2CN , $-\text{COOA}$, Hal, SCF_3 , preferably also t-butyl, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, isopropyl, ethyl or methyl. In particular, R^1 denotes t-butyl, isopropyl, ethyl, CF_3 , methyl, Br, Cl, SCF_3 , $\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, n-propyl, OCH_3 , SCH_3 , n-butyl, $-\text{SCN}$, CH_2CN . R^1 particularly preferably denotes t-butyl or CF_3 .

R^2 preferably denotes Hal, A or OA, in particular Br, cyclopropyl, OCH_3 . Particular preference is furthermore given to H or F.


R^3 preferably denotes H or A, in particular H. R^3 is preferably in the 5-position. In particular, R^3 denotes H or F.

In particularly preferred compounds of the formula I, R^2 and R^3 simultaneously have the meaning H. In further preferred compounds of the formula I, one of the radicals R^2 and R^3 has the meaning H and the other radical has the meaning F.

R^4 preferably denotes one of the following groups if R^5 denotes H:




5 R^5 preferably denotes H or, together with R^4 , adopts one of the following meanings:




in which n, X, R and R^a have the meaning indicated above.

20 R^4 together with R^5 particularly adopts one of the following meanings:



in which R has the meaning indicated above and $N(R^1)_2$ preferably denotes NHR, in particular $NHCH_3$, $NH(CH_2)_3OR^1$, $NR(CH_2)_3OR^1$, $NHSO_2R^1$, $NRSO_2R^1$, $NHSO_2(CH_2)_3NHR$ or $NRSO_2(CH_2)_3NHR$, where $NR(CH_2)_3OR^1$ preferably stands for $NA(CH_2)_3OR^1$, $NRSO_2R^1$ preferably stands for $NASO_2R^1$, and $NRSO_2(CH_2)_3NHR$ preferably stands for $NASO_2(CH_2)_3NHR$. In $NA(CH_2)_3OR^1$, $NASO_2R^1$ and $NASO_2(CH_2)_3NHR$, A preferably stands for H or alkyl, particularly preferably for alkyl and in particular for methyl or ethyl. In $NASO_2R^1$, R^1 preferably stands for alkyl, particularly preferably for CH_2Hal , $(CH_2)_2Hal$ or $(CH_2)_3Hal$ and in particular for CH_2Cl , $(CH_2)_2Cl$ or $(CH_2)_3Cl$.

R^4 together with R^5 very particularly preferably adopts one of the following meanings:



10 in which R has the meaning indicated above, and $N(R^1)_2$ preferably denotes NHR, in particular $NHCH_3$, $NH(CH_2)_3OR^1$ or $NHSO_2(CH_2)_3NHR$.

15 R^4 , R^5 and R^6 preferably denote A or H. Particularly preferably, only one of the radicals denotes A, while the others denote H. In particular, the radicals also simultaneously denote H.


5- and 6-membered ring systems are preferred. 6-membered ring systems are particularly preferred.

20 R^a preferably denotes 1-piperazinyl, N-morpholinyl, NHR or NR_2 .

25 R^6 preferably denotes phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, each of which is unsubstituted or mono- or polysubstituted by Hal, CN, NO_2 , OH, CF_3 , $OCH(CF_3)_2$, $OCOCH_3$ or A. R^6 is preferably not a heteroaromatic radical. In particular, R^6 denotes one of the following groups:


30

35



X denotes O, S or NR and in particular O or S, A has the meaning indicated above, but preferably denotes methyl, and Hal preferably denotes F or Cl.

Particular preference is furthermore given to compounds of the formula I in which R^6 has one of the following meanings:



R^7 preferably denotes H or A, in particular H.

Aryl preferably denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH₂, NO₂, CN, COOH, COOA, CONH₂, NHCOA, NHCONH₂, NHSO₂A, CHO, COA, SO₂NH₂, SO₂A, -CH₂-COOH or -OCH₂-COOH.

Aryl preferably denotes phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methylaminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methylsulfonyl)phenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Heteroaryl preferably denotes a mono- or bicyclic aromatic heterocycle having one or more N, O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, NO₂, NHA, NA₂, OA, COOA or CN.

Heteroaryl particularly preferably denotes a monocyclic saturated or aromatic heterocycle having one N, S or O atom, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA₂, NO₂, COOA or benzyl.





Irrespective of further substitutions, unsubstituted heteroaryl denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.

Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl.

Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another.

The compounds of the formula I can have one or more chiral centres and therefore exist in various stereoisomeric forms. The formula I encompasses all these forms.

Particularly preferred compounds of the formula I are those of the sub-formulae IA to ID:



in which

35 R, R¹, R², R⁶, R⁷ and X have the meanings indicated above


and

R^8 preferably denotes Q and in particular H, CH_2OR , CH_2NR_2 , CH_2R^a , COR^a , $(CH_2)_p-E-(CH_2)_2R^1$, $(CH_2)_n-E-(CH_2)_p-R^a$.

5


Particularly preferred compounds of the formula IA are those of the sub-formulae IA0 to IA5:

10




15

20






25

30



35



in which R, R^a, R¹, R², R³, R⁶ and R⁷ have the meanings indicated above.



30 In particularly preferred compounds of the formula IB, R⁸ has the meaning H.

35 The radicals R⁴ and R⁵ are particularly preferably in the cis-position to one another. The radical R⁶ is furthermore preferably in the trans-position to the radical R⁵.

Preference is given here to a compound of the formula A or B having the following structure:

5

10




and the racemate thereof or other mixtures of the enantiomers.

15

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae I1 to I505:

20


25







I1


30

35




I2







17




18




19




110




I11




I12




I13




I14



I15




I16




I17


35




I18




I19



I20




I21




I22


35




123




124



125








126




127

35




5




133

10



134


15



20


135

25








136


30




137

35







I43




I44




I45




I46




147



148




149




150


35




151



152




153




154


35




155




156




157




158




159




160



161




162




35

163


5




10




15




20



25



30



35

I64


I65

I66

I67


I68

I69




5

170




10

171




15

172




20

173



25


174




30

175


35




176




177




178



179




180




181


35




182




183




184



185




186




187

5




188

10




189

15



190


20



191


25

30




192


35




193




194



195




196




197


35




198




199



I100




I101



I102


35

5




I103

10



I104


15



20


I105

25



I106


30



35


I107

5




I108

10




I109

15



I110


20



25

I111


30



I112


35

5




I113

10




I114

15



I115


20



25


I116

30




35


I117




I118




I119



I120




I121




I122


35




I123




I124



I125




I126




I127

5




I128

10



I129


15



20


I130

25




I131

30




I132

35



I133


5



10


I134

15




I135

20



I136


25




30

I137


35




I138




I139



I140




I141



35


I142

5




I143

10




I144

15




I145

20




I146

25




I147

30




35


I148




I149




I150



I151



I152




I153

30


35

5




I154

10




I155

15




I156

20



I157


25



I158


35

5




I159

10




I160

15



I161


20



25

I162


30



I163


35

5




1164

10




1165

15




1166

20



1167

25




1168

30


35

5




I169

10




I170

15




I171

20



I172


25




I173

30


35




1174




1175




1176




1177




1178




I179



I180




I181




I182


35




I183



I184




I185




I186


35




I187




I188



I189







I190



I191

35



30


35

I192


I193

I194


I195




I196



I197




I198




I199

5




I200

10




I201

15



I202


20



25


I203

30




I204


35




I205




I206



I207




I208




I209

5




I210

10




I211

15




I212

20




I213

25



I214


30



I215


35

5




I216

10




I217

15




I218

20




I219

25



I220


30



35


I221

5




1222

10




1223

15




1224

20



1225

25




1226

30


35

5



1227


10



15

1228


20



25

1229


30



35

1230


5



10


I231

15




20

I232




25

I233




30

I234




35

I235




5

I236




10

I237




15

I238




20

I239



25


I240



35

I241


5



10

I242


15



20

I243


25



30


I244

35




I245

5




I246

10




I247

15




I248

20



I249


30



35


I250

5




I251 ,

10



I252


15



I253 ,


20

25




I254

30




I255


35




1256



1257




1258




1259


35




I260




I261



I262




I263



I264


5

10




1265

15



1266


20



1267

25


30



1268


35

5




1269

10




1270

15




1271

25




1272


35




1273



1274




1275



1276

35


5



10


1277

15




20

1278




25

1279




30

1280




35


1281




I282



I283




I284



I285


35

5




I286

10




I287

20



I288

30




I289

35

5


10



15


I290

20



I291

25




30

I292

35


5



10

1293


15



20

1294


25




30

1295


35




1296




I297




I298



I299



I300




I301

5


10

15




I302

20



I303

25




30

I304


35

5



I305


10



15


I306

20



I307


25




30

I308


35




1309



1310




1311




1312


35




I313




I314



I315




I316



I317


35

5




I318

10




I319

15




I320

20



I321

25




I322

30


35

5




I323

10




I324

20




I325

30




I326


35




I327




I328



I329




I330



I331


35

5




I332

10




I333

15




I334

20




I335

25



I336

30




I337

35

5


10



15

I338


20



25


I339

30




35


I340




1341




1342



1343




1344



1345


35

5




I346

10




I347

15




I348

20



I349


25




I350

30


35




I351




I352




I353



I354




I355




I356

5




I357

10




I358

20




I359

25




I360

30




35


I361




I362




I363



I364




I365




I366


35




10 1367



20 1368




30 1369




1370

5




1371

10




1372

15



1373


20



1374


25

30




1375

35




5

I376




10

I377



15


I378



20

25


I379




30

I380


35




1381



1382




1383




1384


35




I385




I386



I387




I388




I389


35




1390




1391




1392




1393




1394




1395




I396




I397



I398




I399




I400


35




I401



I402




I403




I404


35




I405




I406



I407




I408



I409


35

5




I410

10




I411

20



I412


25




I413

30


35




I414




I415



I416




I417




I418


35




1419




1420




1421



1422




1423




1424


35




1425




1426



1427




1428




1429


35




1430




1431



1432




1433




35


1434




I435




I436



I437




I438




I439


35




1440




1441



1442




1443




1444


35




I445



I446








I447




I448


35




35




I454




I455



I456




I457




35


I458




I459




I460



I461




I462




I463


35



I464




I465




I466

30


35




1467



1468




1469



1470


35

5




1471

10




1472

15



1473


20



25


1474

30




1475


35




1476



1477




1478




1479

5




I480

10




I481

15




I482

20




I483

25



I484


30



I485

35


5



10


1486

15




1487

20




1488

25




1489

30




35


1490




I491




I492



I493




I494




I495


35




1496



1497




1498




1499


35




I500




I501



I502




I503



I504

35



10

The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use may also be made here of variants known per se which are not mentioned here in greater detail.

20

If desired, the starting materials may also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.

25

The reaction is generally carried out in an inert solvent, preferably in the presence of a protonic acid or Lewis acid, such as TFA, HFIP, bismuth(III) salts, ytterbium(III) salts or CAN. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0° and 180°, normally between 0° and 100°, particularly preferably between 15° and 35°C.

30

Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-

35

form or dichloromethane; nitriles, such as acetonitrile; carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene, or mixtures of the said solvents.

5 Compounds of the formula I in which R^7 has a meaning other than H are preferably prepared by alkylation or acylation from the compounds of the formula I in which R^7 denotes H.

10 If desired, a functionally modified amino and/or hydroxyl group in a compound of the formula I can be liberated by solvolysis or hydrogenolysis by conventional methods. This can be carried out, for example, using NaOH or KOH in water, water/THF or water/dioxane at temperatures between 0 and 100°.

15 The reduction of an ester to the aldehyde or alcohol or the reduction of a nitrile to the aldehyde or amine is carried out by methods as are known to the person skilled in the art and are described in standard works of organic chemistry.

20 The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt.

25 Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and

30

35

various organic bases, such as piperidine, diethanolamine and N-methyl-glutamine. The aluminium salts of the compounds of the formula I are likewise included. In the case of certain compounds of the formula I, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts

sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C₁-C₄)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C₁-C₄)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C₁₀-C₁₈)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C₁-C₄)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.

The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.

The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner.

The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-

phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.

5 With regard to that stated above, it can be seen that the term "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
10 The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect
15 to its therapeutic efficacy in the body.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
20 and optionally excipients and/or adjuvants.

Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof
30 of an active ingredient. Furthermore, pharmaceutical formulations of this
35

type can be prepared using a process which is generally known in the pharmaceutical art.

5 Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all
10 processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).

Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

20 Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by
25 comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

30 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the
35 powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate,

may likewise be added in order to improve the availability of the medication after the capsule has been taken.

5 In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, 10 carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, 15 starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by 20 mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such 25 as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, 30 the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the 35 invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-

pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

5

10

Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

15

20

The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

25

30

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

35

The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are cou-

5 pled. The compounds can also be coupled to soluble polymers as targeted
medicament carriers. Such polymers may encompass polyvinylpyrrolidone,
pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxy-
ethylaspartamidophenol or polyethylene oxide polylysine, substituted by
10 palmitoyl radicals. The compounds may furthermore be coupled to a class
of biodegradable polymers which are suitable for achieving controlled
release of a medicament, for example polylactic acid, poly-epsilon-capro-
lactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihy-
10 droxypyrans, polycyanoacrylates and crosslinked or amphipathic block co-
polymers of hydrogels.

15 Pharmaceutical formulations adapted for transdermal administration can
be administered as independent plasters for extended, close contact with
the epidermis of the recipient. Thus, for example, the active ingredient can
be delivered from the plaster by iontophoresis, as described in general
terms in *Pharmaceutical Research*, 3(6), 318 (1986).

20 Pharmaceutical compounds adapted for topical administration can be for-
mulated as ointments, creams, suspensions, lotions, powders, solutions,
pastes, gels, sprays, aerosols or oils.

25 For the treatment of the eye or other external tissue, for example mouth
and skin, the formulations are preferably applied as topical ointment or
cream. In the case of formulation to give an ointment, the active ingredient
can be employed either with a paraffinic or a water-miscible cream base.
30 Alternatively, the active ingredient can be formulated to give a cream with
an oil-in-water cream base or a water-in-oil base.

35 Pharmaceutical formulations adapted for topical application to the eye
include eye drops, in which the active ingredient is dissolved or suspended
in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

5 Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

10 Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with
15 a liquid as carrier substance encompass active-ingredient solutions in water or oil.

20 Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

25 Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

30 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in
35 single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition

of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.

Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.

5

It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.

10

A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

15

20

25

30

35

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, sol-

40

vates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

The invention also relates to a set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.

The medicaments from Table 1 are preferably, but not exclusively, combined with the compounds of the formula I. A combination of the formula I and medicaments from Table 1 can also be combined with compounds of the formula V.

Table 1.		
Alkylating agents	Cyclophosphamide	Lomustine
	Busulfan	Procarbazine
	Ifosfamide	Altretamine
	Melphalan	Estramustine phosphate
	Hexamethylmelamine	Mechloroethamine
	Thiotepa	Streptozocin
	chloroambucil	Temozolomide
	Dacarbazine	Semustine
	Carmustine	
Platinum agents	Cisplatin	Carboplatin

5		Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Ormiplatin Iproplatin	ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464 (Hoffmann- La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
10	Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-fluorouracil Floxuridine 2-chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-fluorodesoxycytidine Methotrexate Idatrexate	Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharma) DMDC (Hoffmann-La Roche) Ethinylcytidine (Taiho)
20	Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10- hydroxycamptothecin Topotecan Dexrazoxanet (TopoTarget) Pixantrone (Novuspharma) Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharma)	Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma- Tau) Diflomotecan (Beaufour- Lipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)
35	Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin	Amonafide Azonafide Anthrapyrazole Oxantrazole Losoxantrone Bleomycin sulfate (Blenoxan) Bleomycinic acid

5

10

15

20

25

30

35

	Therarubicin Idarubicin Rubidazon Plicamycinp Porfiromycin Cyanomorpholinodoxo- rubicin Mitoxantron (Novantron)	Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceuticals)
Antimitotic agents	Paclitaxel Docetaxel Colchicine Vinblastine Vincristine Vinorelbine Vindesine Dolastatin 10 (NCI) Rhizoxin (Fujisawa) Mivobulin (Warner- Lambert) Cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis) Epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) Cryptophycin 52 (Eli Lilly) Vinflunine (Fabre) Auristatin PE (Teikoku Hormone) BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) Taxoprexin (Protarga)	SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTA Medica) ER-86526 (Eisai) Combretastatin A4 (BMS) Isohomohalichondrin-B (PharmaMar) ZD 6126 (AstraZeneca) PEG-Paclitaxel (Enzon) AZ10992 (Asahi) IDN-5109 (Indena) AVLB (Prescient NeuroPharma) Azaepothilon B (BMS) BNP- 7787 (BioNumerik) CA-4-Prodrug (OXiGENE) Dolastatin-10 (NrH) CA-4 (OXiGENE)
Aromatase inhibitors	Aminoglutethimide Letrozole Anastrozole Formestan	Exemestan Atamestan (BioMedicines) YM-511 (Yamanouchi)
Thymidylate synthase inhibitors	Pemetrexed (Eli Lilly) ZD-9331 (BTG)	Nolatrexed (Eximias) CoFactor™ (BioKeys)
DNA antagonists	Trabectedin (PharmaMar) Glufosfamide (Baxter International)	Mafosfamide (Baxter International) Apaziquone (Spectrum)

	Albumin + 32P (Isotope Solutions)	Pharmaceuticals)
	Thymectacin (NewBiotics)	O6-Benzylguanine (Paligent)
	Edotreotid (Novartis)	
5	Farnesyl transferase inhibitors	Arglabin (NuOncology Labs) Ionafernib (Schering-Plough) BAY-43-9006 (Bayer)
		Tipifarnib (Johnson & Johnson) Perillyl alcohol (DOR BioPharma)
10	Pump inhibitors	CBT-1 (CBA Pharma) Tariquidar (Xenova) MS-209 (Schering AG)
		Zosuquidar trihydrochloride (Eli Lilly) Biricodar dicitrate (Vertex)
15	Histone acetyl transferase inhibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG)
		Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
20	Metalloproteinase inhibitors Ribonucleoside reductase inhibitors	Neovastat (Aeterna Laboratories) Marimastat (British Biotech) Gallium maltolate (Titan) Triapin (Vion)
		CMT -3 (CollaGenex) BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for Health)
	TNF-alpha agonists/ antagonists	Virulizin (Lorus Therapeutics) CDC-394 (Celgene)
		Revimid (Celgene)
25	Endothelin-A receptor antagonists	Atrasentan (Abbot) ZD-4054 (AstraZeneca)
		YM-598 (Yamanouchi)
30	Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) LGD-1550 (Ligand)
		Alitretinoin (Ligand)
35	Immuno-modulators	Interferon Oncophage (Antigenics) GMK (Progenics) Adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) JRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) Synchrovax vaccines (CTL
		Dexosome therapy (Anosys) Pentrix (Australian Cancer Technology) JSF-154 (Tragen) Cancer vaccine (Intercell) Norelin (Biostar) BLP-25 (Biomira) MGV (Progenics)

5

10

15

20

25

30

35

	Immuno) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVax)	!3-Alethin (Dovetail) CLL-Thera (Vasogen)
Hormonal and antihormonal agents	Oestrogens Conjugated oestrogens Ethinylloestradiol chlorotrianisene Idenestrol Hydroxyprogesterone caproate Medroxyprogesterone Testosterone Testosterone propionate Fluoxymesterone Methyltestosterone Diethylstilbestrol Megestrol Tamoxifen Toremofin Dexamethasone	Prednisone Methylprednisolone Prednisolone Aminoglutethimide Leuprolide Goserelin Leuporelin Bicalutamide Flutamide Octreotide Nilutamide Mitotan P-04 (Novogen) 2-Methoxyoestradiol (EntreMed) Arzoxifen (Eli Lilly)
Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin-Gadolinium (Pharmacyclics)	Pd-Bacteriopheophorbid (Yeda) Lutetium-Texaphyrin (Pharmacyclics) Hypericin
Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide(Sugen/Pharm acia) ZD1839 (AstraZeneca) Erlotinib (Oncogene Science) Canertjnib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) Vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)

	EKB-569 (Wyeth)	
5	Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-100 (gal3 antagonist, GlycoGenesys) G17DT immunogen (gastrin inhibitor, Aphton) Efaproxiral (oxygenator, Allos Therapeutics) PI-88 (heparanase inhibitor, Progen) Tesmilifen (histamine antagonist, YM BioSciences) Histamine (histamine H2 receptor agonist, Maxim) Tiazofurin (IMPDH inhibitor, Ribapharm) Cilengitide (integrin antagonist, Merck KGaA) SR-31747 (IL-1 antagonist, Sanofi-Synthelabo) CCI-779 (mTOR kinase inhibitor, Wyeth) Exisulind (PDE-V inhibitor, Cell Pathways) CP-461 (PDE-V inhibitor, Cell Pathways) AG-2037 (GART inhibitor, Pfizer) WX-UK1 (plasminogen activator inhibitor, Willex) PBI-1402 (PMN stimulant, ProMetic LifeSciences) Bortezomib (proteasome inhibitor, Millennium) BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech) Seocalcitol (vitamin D receptor agonist, Leo) 131-I-TM-601 (DNA antagonist, TransMolecular) Eflornithin (ODC inhibitor, ILEX Oncology) Minodronic acid (osteoclast inhibitor, Yamanouchi) Indisulam (p53 stimulant, Eisai) Aplidin (PPT inhibitor, PharmaMar) Rituximab (CD20 antibody, Genentech) Gemtuzumab (CD33 antibody, Wyeth Ayerst) PG2 (haematopoiesis promoter, Pharmagenesis) Immunol™ (triclosan mouthwash, Endo) Triacetyluridine (uridine prodrug, Wellstat) SN-4071 (sarcoma agent, Signature BioScience) TransMID-107™ (immunotoxin, KS Biomedix) PCK-3145 (apoptosis promoter, Procyon)
10		
15		
20		
25		
30		
35		

	SRL-172 (T-cell stimulant, SR Pharma) TLK-286 (glutathione-S transferase inhibitor, Telik) PT-100 (growth factor agonist, Point Therapeutics) Midostaurin (PKC inhibitor, Novartis) Bryostatin-1 (PKC stimulant, GPC Biotech) CDA-II (apoptosis promoter, Everlife) SDX-101 (apoptosis promoter, Salmedix) Ceflatonin (apoptosis promoter, ChemGenex)	Doranidazole (apoptosis promoter, Pola) CHS-828 (cytotoxic agent, Leo) Trans-retinic acid (differentiator, NIH) MX6 (apoptosis promoter, MAXIA) Apomine (apoptosis promoter, ILEX Oncology) Urocidin (apoptosis promoter, Bioniche) Ro-31-7453 (apoptosis promoter, La Roche) Brostallicin (apoptosis promoter, Pharmacia)
--	--	---

15 The compounds of the formula I are preferably combined with known anti-cancer agents:

The present compounds are also suitable for combination with known anti-cancer agents. These known anti-cancer agents include the following:

20 oestrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and other angiogenesis inhibitors. The present compounds are particularly suitable for administration at

25 the same time as radiotherapy. The synergistic effects of inhibition of VEGF in combination with radiotherapy have been described by specialists (see WO 00/61186).

"Oestrogen receptor modulators" refers to compounds which interfere with

30 or inhibit the binding of oestrogen to the receptor, regardless of mechanism. Examples of oestrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl 2,2-dimethylpropanoate,

35 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646.

"Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate.

"Retinoid receptor modulators" refers to compounds which interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide and N-4-carboxyphenyl-retinamide.

"Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on the cellular function or inhibit or interfere with cell division, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.

Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profirromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methylpyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)bis-mu-(hexane-1,6-diamine)mu-[diamine-platinum(II)]bis[diamine(chloro)platinum(II)] tetrachloride, diarisidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplastone, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-aziridinyl-4-methylsulfonyldaunorubicin (see WO 00/50032).

Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exobenzylidenechartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxyetoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]-quinolin-7-one and dimesna.

"Antiproliferative agents" include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and anti-metabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine, ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitfur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-

methylenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-mannoheptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4-thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo-(7.4.1.0.0)tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabinofuranosyl cytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. "Antiproliferative agents" also include monoclonal antibodies to growth factors other than those listed under "angiogenesis inhibitors", such as trastuzumab, and tumour suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,069,134, for example).

Particular preference is given to the use of the compound according to the invention for the treatment and prophylaxis of tumour diseases.

The tumour is preferably selected from the group of tumours of the squamous epithelium, bladder, stomach, kidneys, head and neck, oesophagus, cervix, thyroid, intestine, liver, brain, prostate, urogenital tract, lymphatic system, stomach, larynx and/or lung.


The tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.


The invention also encompasses a method for the treatment of a patient who has a neoplasm, such as a cancer, by administration of

a) one or more of the compounds of the formula I:

b) and one or more of the compounds of the formula V or acid-addition salts thereof, in particular hydrochlorides:



in which Y' and Z' each, independently of one another, denote O or N, R⁶ and R⁷ each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, n denotes an integer between 2 and 6, each inclusive, and R⁸ and R⁹ are each, independently of one another, preferably in the meta- or para-position and are selected from the group:



where the first and second compound are administered simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of the neoplasm.

5 The combination of the compounds of the formula I with the compounds of the formula V and other pentamidine analogues results in a synergistic action in the inhibition of neoplasias. Combinations comprising the compounds of the formula V are mentioned, for example, in WO 02058684.


10 The mechanism of action of pentamidine or derivatives thereof has not been clearly explained at present: pentamidine or derivatives thereof appears to have pleiotropic actions since it results in a decrease in DNA, RNA and protein synthesis. It was recently described that pentamidine is a capable inhibitor of PRL1, -2 and 3 phosphatases (Pathak et al., 2002) and tyrosine phosphatases, and overexpression thereof is accompanied by neoplastic malignant tumours in humans. On the other hand, it has been described that pentamidine is a medicament which binds to the DNA
15 20 minor groove (Puckowska et al., 2004) and is able to exert its action via disturbance of gene expression and/or DNA synthesis.

25 The appended experiments show that:

- both pentamidine and also the compounds of the formula I maintain cells in the G2/M cell cycle.
- the combination of pentamidine and compounds of the formula I have
30 additive to synergistic actions on cell proliferation.


Other suitable pentamidine analogues include stilbamidine (G-1) and hydroxystilbamidine (G-2) and indole analogues thereof (for example G-3):

35



5


(G-1)



10

(G-2)

and



15

20

(G-3)

Each amidine unit may be replaced, independently of one another, by one of the units defined above for R^8 and R^{11} . As in the case of benzimidazoles and pentamidines, salts of stilbamidine, hydroxystilbamidine and indole derivatives thereof are also suitable for the process according to the invention. Preferred salts include, for example, dihydrochloride and methanesulfonate salts.

25

30

Still other analogues are those which fall under a formula which are provided in one of the US Patents No. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395 or the US patent application with the publication No. US 2002/0019437 A1, each of which is incorporated in its entirety by way of reference. Illustrative ana-

35

logues include 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,3-bis(4'-(N-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,3-bis(4'-(4-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 2,5-bis[4-amidinophenyl]furan, 2,5-bis[4-amidinophenyl]furan bisamide oxime, 2,5-bis[4-amidinophenyl]furan bis-O-methylamide oxime, 2,5-bis[4-amidinophenyl]furan bis-O-ethylamide oxime, 2,8-diamidinodibenzothiophene, 2,8-bis(N-isopropylamidino)carbazole, 2,8-bis(N-hydroxyamidino)carbazole, 2,8-bis(2-imidazoliny)l)dibenzothiophene, 2,8-bis(2-imidazoliny)l)-5,5-dioxo-dibenzothiophene, 3,7-diamidinodibenzothiophene, 3,7-bis(N-isopropylamidino)dibenzothiophene, 3,7-bis(N-hydroxyamidino)dibenzothiophene, 3,7-diaminodibenzothiophene, 3,7-dibromodibenzothiophene, 3,7-dicyanodibenzothiophene, 2,8-diamidinodibenzofuran, 2,8-di-(2-imidazoliny)l)-dibenzofuran, 2,8-di-(N-isopropylamidino)dibenzofuran, 2,8-di-(N-hydroxylamidino)dibenzofuran, 3,7-di-(2-imidazoliny)l)dibenzofuran, 3,7-di-(isopropylamidino)dibenzofuran, 3,7-di-(A-hydroxylamidino)dibenzofuran, 2,8-dicyanodibenzofuran, 4,4'-dibromo-2,2'-dinitrobiphenyl, 2-methoxy-2'-nitro-4,4'-dibromobiphenyl, 2-methoxy-2'-amino-4,4'-dibromobiphenyl, 3,7-dibromodibenzofuran, 3,7-dicyanodibenzofuran, 2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 2,5-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]pyrrole, 2,6-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]pyridine, 1-methyl-2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 1-methyl-2,5-bis[5-(2-imidazolyl)-2-benzimidazolyl]pyrrole, 1-methyl-2,5-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyrrole, 2,6-bis(5-amidino-2-benzimidazolyl)pyridine, 2,6-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyridine, 2,5-bis(5-amidino-2-benzimidazolyl)furan, 2,5-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]furan, 2,5-bis(5-N-isopropylamidino-2-benzimidazolyl)furan, 2,5-bis(4-guanyphenyl)furan, 2,5-bis(4-guanyphenyl)-3,4-dimethylfuran, 2,5-di-p-[2-(3,4,5,6-tetrahydropyrimidyl)phenyl]furan, 2,5-bis[4-(2-imidazoliny)l)phenyl]furan, 2,5-bis[4-(2-tetrahydropyrimidinyl)]phenyl]p-(tolyl)oxyfuran, 2,5-bis[

{4-(2-imidazoliny)}phenyl]-3-p-(tolylloxy)furan, 2,5-bis{4-[5-(N-2-aminoethyl-
 amido)benzimidazol-2-yl]phenyl}furan, 2,5-bis[4-(3a,4,5,6,7,7a-hexahydro-
 1H-benzimidazol-2-yl)phenyl]furan, 2,5-bis[4-(4,5,6,7-tetrahydro-1H-1,3-
 diazepin-2-yl)phenyl]furan, 2,5-bis(4-N,N-dimethylcarboxhydrazidophenyl)-
 furan, 2,5-bis{4-[2-(N-2-hydroxyethyl)imidazoliny]}phenyl}furan, 2,5-bis[4-
 (N-isopropylamidino)phenyl]furan, 2,5-bis{4-[3-(dimethylamino-
 propyl)amidino]phenyl}furan, 2,5-bis{4-[N-(3-aminopropyl)amidino]phenyl}-
 furan, 2,5-bis[2-(imidazoliny)phenyl]-3,4-bis(methoxymethyl)furan, 2,5-bis-
 [4-N-(dimethylaminoethyl)guanyl]phenylfuran, 2,5-bis{4-[(N-2-hydroxy-
 ethyl)guanyl]phenyl}furan, 2,5-bis[4-N-(cyclopropylguanyl)phenyl]furan,
 2,5-bis[4-(N,N-diethylaminopropyl)guanyl]phenylfuran, 2,5-bis[4-[2-(N-
 ethylimidazoliny)]phenyl]furan, 2,5-bis{4-[N-(3-pentylguanyl)]}phenylfuran,
 2,5-bis[4-(2-imidazoliny)phenyl]-3-methoxyfuran, 2,5-bis[4-(N-isopropyl-
 amidino)phenyl]-3-methylfuran, bis[5-amidino-2-benzimidazolyl]methane,
 bis[5-(2-imidazolyl)-2-benzimidazolyl]methane, 1,2-bis[5-amidino-2-benz-
 imidazolyl]ethane, 1,2-bis[5-(2-imidazolyl)-2-benzimidazolyl]ethane, 1,3-
 bis[5-amidino-2-benzimidazolyl]propane, 1,3-bis[5-(2-imidazolyl)-2-benz-
 imidazolyl]propane, 1,4-bis[5-amidino-2-benzimidazolyl]propane, 1,4-bis[5-
 (2-imidazolyl)-2-benzimidazolyl]butane, 1,8-bis[5-amidino-2-benz-
 imidazolyl]octane, trans-1,2-bis[5-amidino-2-benzimidazolyl]ethene, 1,4-
 bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-butene, 1,4-bis[5-(2-imidazolyl)-2-
 benzimidazolyl]-2-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-
 methylbutane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-ethylbutane,
 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-
 imidazolyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-imidazolyl)-
 2-benzimidazolyl]-1,3-butadiene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-
 2-methyl-1,3-butadiene, bis[5-(2-pyrimidyl)-2-benzimidazolyl]methane, 1,2-
 bis[5-(2-pyrimidyl)-2-benzimidazolyl]ethane, 1,3-bis[5-amidino-2-benz-
 imidazolyl]propane, 1,3-bis[5-(2-pyrimidyl)-2-benzimidazolyl]propane, 1,4-
 bis[5-(2-pyrimidyl)-2-benzimidazolyl]butane, 1,4-bis[5-(2-pyrimidyl)-2-benz-
 imidazolyl]-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-butene,
 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methylbutane, 1,4-bis[5-(2-pyri-

midyl)-2-benzimidazolyl]-2-ethylbutane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1,3-butadiene and 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-methyl-1,3-butadiene, 2,4-bis(4-guanylphenyl)pyrimidine, 2,4-bis(4-imidazolin-2-yl)-pyrimidine, 2,4-bis[(tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine, 2-(4-[N-i-propylguanyl]phenyl)-4-(2-methoxy-4-[N-i-propylguanyl]phenyl)pyrimidine, 4-(N-cyclopentylamidino)-1,2-phenylenediamine, 2,5-bis[2-(5-amidino)-benzimidazolyl]furan, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]furan, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]furan, 2,5-bis[2-(5-amidino)benzimidazolyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]pyrrole, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]pyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]pyrrole, 1-methyl-2,5-bis[2-(5-amidino)benzimidazolyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]-1-methylpyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]-1-methylpyrrole, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]thiophene, 2,6-bis[2-{5-(2-imidazolino)}benzimidazolyl]pyridine, 2,6-bis[2-(5-amidino)benzimidazolyl]pyridine, 4,4'-bis[2-(5-N-isopropylamidino)benzimidazolyl]-1,2-diphenylethane, 4,4'-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]-2,5-diphenylfuran, 2,5-bis[2-(5-amidino)benzimidazolyl]benzo[b]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]benzo[b]furan, 2,7-bis[2-(5-N-isopropylamidino)benzimidazolyl]fluorine, 2,5-bis[4-(3-(N-morpholinopropyl)carbamoyl)phenyl]furan, 2,5-bis[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N-methyl-3-N-phenylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N,N8,N11-trimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[3-amidinophenyl]furan, 2,5-bis[3-(N-isopropylamidino)amidinophenyl]furan, 2,5-bis[3-[(N-(2-dimethylaminoethyl)amidino]phenyl]furan, 2,5-bis[4-(N-2,2,2-trichloroethoxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-thioethylcarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-benzyloxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-phenoxycarbonyl)amidinophenyl]furan,

2,5-bis[4-(N-(4-fluoro)phenoxy-carbonyl)amidinophenyl]furan, 2,5-bis[4-(N-(4-methoxy)phenoxy-carbonyl)amidinophenyl]furan, 2,5-bis[4-(1-acetoxy-ethoxy-carbonyl)amidinophenyl]furan and 2,5-bis[4-(N-(3-fluoro)phenoxy-carbonyl)amidinophenyl]furan. Processes for the preparation of one of the
5 above compounds are described in US patents No. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395 or the US patent application with the publication no. US 2002/0019437 A1.

10 Pentamidine metabolites are likewise suitable in the antiproliferative combination according to the invention. Pentamidine is rapidly metabolised in the body to at least seven primary metabolites. Some of these metabolites have one or more actions in common with pentamidine. Pentamidine
15 metabolites have an antiproliferative action when combined with a benzimidazole or an analogue thereof.


Seven pentamidine analogues are shown below.

20

25

30

35



25 The combinations according to the invention of compounds of the formula I and formula V or analogues thereof and metabolites thereof are suitable for the treatment of neoplasms. Combination therapy can be carried out alone or in combination with another therapy (for example operation, irradiation, chemotherapy, biological therapy). In addition, a person whose risk of developing a neoplasm is greater (for example someone who is

30 genetically predisposed or someone who previously had a neoplasm) can be given prophylactic treatment in order to inhibit or delay neoplasm formation.

The invention likewise relates to the combination of kinesin ATPase Eg5/KSP with the compounds of the formula V, pentamidine, analogues thereof and/or metabolites thereof.

5 The dosage and frequency of administration of each compound in the combination can be controlled independently. For example, one compound may be administered orally three times daily, while the second compound may be administered intramuscularly once per day. The compounds may
10 also be formulated together, leading to administration of both compounds.

The antiproliferative combinations according to the invention can also be provided as components of a pharmaceutical package. The two medica-
15 ments can be formulated together or separately and in individual dosage amounts.

Under another aspect, the invention encompasses a method for the treat-
20 ment of a patient who has a neoplasm, such as a cancer, by administration of a compound of the formula (I) and (V) in combination with an antiprolif-
erative agent. Suitable antiproliferative agents encompass those provided in Table 1.


25 Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: if necessary, water is added, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl
30 acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. R_f values on silica gel; eluent: ethyl acetate/methanol 9:1.

35 Mass spectrometry (MS): EI (electron impact ionisation) M⁺
FAB (fast atom bombardment) (M+H)⁺
ESI (electrospray ionisation) (M+H)⁺


APCI-MS (atmospheric pressure chemical ionisation – mass spectrometry)
(M+H)⁺

Example 1

5



10



15

rac-1

rac-2

a. Reaction in the presence of trifluoroacetic acid (TFA)

20

The solution of the TFA salt of 4-*tert*-butylaniline in acetonitrile (4-*tert*-butylaniline (0.50 g, 3.35 mmol) was taken up in acetonitrile (4 ml), cooled to 0°C and TFA (0.38 g, 3.35 mmol) was slowly added with stirring) was added rapidly to a solution, cooled to 0°C, of an equimolar amount of benzaldehyde and an equimolar amount of the substituted 3,4-dihydro-2H-pyran in acetonitrile (2 ml), and the mixture was stirred at this temperature for a further 60 min. The reaction solution was

evaporated to dryness and separated by column chromatography, giving a colourless solid, which proved to be the isomer mixture of the respective racemic *trans/cis* compound.

30

35

In order to separate the *cis/trans* isomers, the solid was taken up in 0.1 N HCl in isopropanol (20 ml), 100 ml of both diethyl ether and cyclohexane

were added, and the product was crystallised overnight at 4°C. The colourless solid was filtered off, washed with a little diethyl ether and dried, giving the colourless compound rac-1 hydrochloride. The mother liquor was evaporated to dryness in a rotary evaporator, and the *cis* isomer was purified by column chromatography and converted into the hydrochloride, giving rac-2.


Relatively small amounts of rac-1 and rac-2 were separated into the corresponding enantiomers by chiral HPLC (2x Chiralpak AD 20µm, eluent: methanol) and reconverted into the hydrochlorides.

The individual compounds can subsequently be processed further by known methods.

For example, they can be esterified using a carboxylic acid. It is likewise possible to convert the free hydroxyl group into a leaving group using methanesulfonyl chloride and into the corresponding amines or nitriles by reaction with nucleophiles, such as, for example, NH₃ or NaCN.

All further compounds of the formula I can be obtained analogously using the corresponding precursors. The following examples relate to pharmaceutical compositions.

Example 2



a.

The alcohol 1 (1.00 g, 2.75 mmol) were suspended in 10 ml of DCM, triethylamine (0.76 ml, 5.48 mmol) was added at RT, and methanesulfonyl chloride (0.22 ml, 2.84 mmol) was subsequently added dropwise, likewise at RT. The solution was stirred further overnight, the solvent was removed, the crude substance was taken up in ethyl acetate (50 ml) and extracted 2 x with water. The organic phase was dried, filtered, and the solvent was removed, giving 1.15 g (2.61 mmol, 95%) of yellowish crystals of high purity which was characterised as comp. 2.

b.

Compound 2 (1.00 g, 2.27 mmol) was dissolved in a saturated solution of ammonia in MeOH (about 5.9 M, 20 ml) and stirred in a pressure flask at 100°C for 18 h.


The excess ammonia was evaporated off, the solvent was removed, and the residue was processed further without further purification, giving 0.81 g (2.22 mmol, 98%) of yellowish crystals of compound 3.

c.

The amine 3 (0.75 g, 2.07 mmol) were dissolved in 15 ml of DCM, triethylamine (0.57 ml, 4.14 mmol) was added at RT, and 3-chloropropane-sulfonyl chloride (0.37 ml, 2.07 mmol) was subsequently added dropwise, likewise at RT. The solution was stirred further overnight, the solvent was removed, the crude substance was taken up in ethyl acetate (50 ml) and extracted 2 x with water. The organic phase was dried, filtered, and the solvent was removed, giving 0.85 g (1.67 mmol, 82%) of yellowish crystals, which was characterised as comp. 4.

d.

Compound 4 (0.5 g, 0.99 mmol) was dissolved in 10 ml of an 8 M solution of methylamine in methanol and stirred in a pressure flask at 100°C for 18 h. The product was subsequently precipitated by addition of water, filtered off and purified by column chromatography (methanol/ethyl acetate/cyclohexane, gradient), giving 373 mg (0.75 mmol, 75%) of a colourless solid, which was converted into the hydrochloride in the usual manner.



e.

The amine 3 (250 mg, 0.69 mmol) were dissolved in 4 ml of DCM, triethylamine (0.19 ml, 1.38 mmol) was added at RT, and 2-chloropropane-sulfonyl chloride (0.37 ml, 2.07 mmol) was subsequently added dropwise, likewise at RT. The solution was stirred further overnight, the solvent was removed, the crude substance was taken up in ethyl acetate (50 ml) and

extracted 2 x with water. The organic phase was dried, filtered, and the solvent was removed, giving 312 mg (0.69 mmol, 100%) of yellowish crystals, which was characterised as comp. 6.

5

f.

10

The sulfonamide 6 (70 mg, 0.16 mmol) was dissolved in a 2 M solution of dimethylamine in THF (1.00 ml) and stirred overnight at RT. The solvent was removed, and the residue was purified by preparative reversed-phase HPLC (acetonitrile/water gradient with 0.1% of TFA), giving 49 mg (0.08 mmol, 52%) of a colourless solid.

15

20

25

30

35

Example A: Assay I

5 The efficacy of the compounds according to the invention can be determined, for example, via the Eg5 ATPase activity, which is measured via an enzymatic regeneration of the product ADP to ATP by means of pyruvate kinase (PK) and subsequent coupling to an NADH-dependent lactate dehydrogenase (LDH) reaction. The reaction can be monitored via the
10 change in absorbance at 340 nm by coupling to the NADH-dependent LDH. The regeneration of the ATP simultaneously ensures that the substrate concentration remains constant. The change in absorbance per time unit are analysed graphically and a linear regression carried out in the
15 visually linear region of the reaction.

Example B: Assay II

20 The combination of the antiprotozoic pentamidine and the inhibitors of kinesin ATPase Eg5/KSP results in increased inhibitory effects in cell proliferation tests with the colon carcinoma cell line HCT116.

25 Eg5 inhibitors adversely affect the ATPase activity and inhibit the course of the cell cycle owing to an error in the separation of the spindle poles.

30 The determination of the efficacy of the compounds of the formula I according to the invention in combination with compounds of the formula V and/or medicaments from Table I can be demonstrated as follows in combination assays:

35 10^3 to 10^4 cells of a defined cell line (HCT116, Colo 205, MDA-MB 231, etc.) are sown into each well of a 96-well microtitre plate and cultivated overnight under standard conditions. For the substances of the combina-

tion to be tested, 10-50 mM stock solutions in DMSO were prepared. Dilution series (generally 3-fold dilution steps) of the individual substances were combined with one another in the form of a pipetting scheme (see scheme below), while maintaining a DMSO final concentration of 0.5% (v/v). Next morning, the substance mixtures were added to the cells, which were incubated under culture conditions for a further 48 hours. At the end of the cultivation, Crystal Violet staining of the cells was carried out. After extraction of the Crystal Violet from the fixed cells, the absorption at 550 nm was measured spectrophotometrically. It can be used as a quantitative measure of the adherent cells present.

Scheme

Compounds of the formula I

←

	1	2	3	4	5	6	7	8	9	10	11	12
A		81 y	27 y	9 y	3 y	y	0					
B	81 x								empty	empty	empty	
C	27 x								0.5% DMS O	0.5% DMS O	0.5% DMS O	
D	9 x											
E	3 x											
F	x											
G	0											
H												

Compounds of the formula V

↑

The following examples relate to medicaments:

Example C: Injection vials

5 A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions.
10 Each injection vial contains 5 mg of active ingredient.

Example D: Suppositories

15 A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example E: Solution

20 A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to
25 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

Example F: Ointment

30 500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.

35

Example G: Tablets

5 A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose,
1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is
pressed in a conventional manner to give tablets in such a way that each
tablet contains 10 mg of active ingredient.

Example H: Dragees

10 Tablets are pressed analogously to Example E and subsequently coated in
a conventional manner with a coating of sucrose, potato starch, talc, traga-
canth and dye.

Example I: Capsules

15 2 kg of active ingredient of the formula I are introduced into hard gelatine
capsules in a conventional manner in such a way that each capsule con-
tains 20 mg of the active ingredient.

Example J: Ampoules

25 A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled
water is sterile filtered, transferred into ampoules, lyophilised under sterile
conditions and sealed under sterile conditions. Each ampoule contains
10 mg of active ingredient.

30


35

Patent Claims

1. Compounds of the formula I

5

10



in which

15

W

denotes CH or N,

20

 $R^1, R^2, R^3,$

independently of one another, denote H, A, aryl, heteroaryl, Hal, $-(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, R, NR- NR_2 , $X(CY_2)_nXR$, $X(CY_2)_nY$, $(CY_2)_n$ -cycloalkyl, $(CY_2)_nCH=CH_2$, cycloalkyl, $-SCH_3$, $-SCN$, $-CF_3$, $-OCF_3$, $-OA$, $-(CY_2)_n-OH$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$, $-(CY_2)_n-Hal$, $-(CY_2)_n-Y$, $-(CY_2)_n-NR_2$, $(CY_2)_n-OA$, $(CY_2)_n-OCOA$, $-SCF_3$, $(CY_2)_n-CONR_2$, $-(CY_2)_n-NHCOA$, $-(CY_2)_n-NHSO_2A$, SF_5 , $Si(CH_3)_3$, $CO-(CY_2)_n-CH_3$, $-(CY_2)_n$ -N-pyrrolidone, $(CH_2)_nNR_2$, NR_2 , NCO , $(CH_2)_nCOOR$, $NCOOR$, $(CH_2)_nOH$, $NR(CH_2)_nNR_2$, $C(OH)R_2$, $NR(CH_2)_nOR$, $NCOR$, $(CH_2)_n$ -aryl, $(CH_2)_n$ -heteroaryl, $(CH_2)_nR^1$, $(CH_2)_nX(CH_2)_n$ -aryl, $(CH_2)_nX(CH_2)_n$ -heteroaryl, $(CH_2)_nCONR_2$, $XCONR(CH_2)_nNR_2$, $N[(CH_2)_nXCOOR]CO(CH_2)_n$ -aryl,


30

35

5		$N[(CH_2)_nXR]CO(CH_2)_n\text{-aryl,}$ $N[(CH_2)_nXR]CO(CH_2)_nX\text{-aryl,}$ $N[(CH_2)_nXR]SO_2(CH_2)_n\text{-aryl,}$ $N[(CH_2)_nNR_2]CO(CH_2)_n\text{-aryl,}$ $N[(CH_2)_nNR_2]CO(CH_2)_nNR\text{-aryl,}$ $N[(CH_2)_nNR_2]SO_2(CH_2)_n\text{-aryl,}$ $N[(CH_2)_nXR]CO(CH_2)_n\text{-heteroaryl,}$
10		$N[(CH_2)_nXR]CO(CH_2)_nX\text{-heteroaryl, CO-aryl,}$ $SO_2\text{-aryl, } N[(CH_2)_nXR]SO_2(CH_2)_n\text{-heteroaryl,}$ $N[(CH_2)_nNR_2]CO(CH_2)_n\text{-heteroaryl,}$ $N[(CH_2)_nNR_2]CO(CH_2)_nNR\text{-heteroaryl,}$
15		R^1 and R^3 together also denote $-N-C(CF_3)=N-$, $-N-CR=N-$, $-N=N=N-$ and where non-adjacent CY_2 groups may also be replaced by X
20	Y	denotes H, A, Hal, OR, E- R^1 ,
25	E	denotes $-NR^1SO_2-$, $-SO_2NR^1-$, $-CONR^1-$, $-NR^1CO-$, $-COO-$, $OO-$, CO , $-SO_2-$, $-X-$, NR^1CONR^1- , $-OCONR^1-$, $-NR^1COO-$, $-CSNR^1-$, $-NR^1CS-$, $-NR^1CSNR^1-$, $-SCONR^1-$, $-NR^1COS-$, $-OCSNR^1-$, NR^1CSO- , $SCSNR^1-$, $-NR^1CSS$ or a single bond
30	A	denotes alkyl or cycloalkyl, in which one or more H atoms may be replaced by Hal,
35	Hal	denotes F, Cl, Br or I


- R denotes H or A, in the case of geminal radicals R together also $-(CH_2)_5-$, $-(CH_2)_4-$ or $-(CH_2)_n-X-(CH_2)_n$,
- 5 X denotes O, S or NR^1 ,
- R^6 denotes phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, each of which is unsubstituted or mono- or polysubstituted by Hal, CN, NO_2 , OH, CF_3 , $OCH(CF_3)_2$, $OCOCH_3$ or A,
- 10 R^7 denotes $(C=O)-R$, $(C=O)-NR_2$, $(C=O)-OR$, H or A
- 15 and
- n denotes 0, 1, 2, 3, 4, 5, 6 or 7
- 20 and solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
- 25 2. Compounds according to Claim 1 in which R^1 denotes A, CF_3 , OCF_3 , SA, SCN, CH_2CN , $-OCHO$, Hal, SCF_3 , t-butyl, $-CH(CH_3)CH_2CH_3$, isopropyl, ethyl or methyl.
- 30 3. Compounds according to Claim 1 or 2 in which R^2 denotes H.
- 35 4. Compounds according to one or more of Claims 1-3 in which R^3 denotes H.

5. Compounds according to one or more of Claims 1-4 in which R^6 denotes one of the following groups:



7. Compounds of the sub-formulae I1 to I59:


5



I1

10


15



I2

20


25




I3

30


35




14



15




16




17

5




18

10



19


20



110

25


30



35

111


5



I12

10


15



I13

20


25



I14


30

35



I15

5




116

10


15

20



117


25



118


30

35




119

5




I20

10




I21

15



I22


20



I23

25


30



I24


35

5




125

10




126

15



127


20



128

25


30



129


35

5




130

10




131

15



132


20



133

25


30



134


35

5




135

10




136

15



137


20



138

25


30



139


35

5



140


10



15


141

20



142

25




30

143


35

5




144

10



145


20



25

146


30



35


147

5



148


10



149

15


20



150

25


30



151


35

5



152


10



153

15


20



154

25


30



155


35

5




156

10




157

20



158


30



35


159

8. Process for the preparation of compounds of the formula I according to Claims 1-6 and salts, solvates, tautomers and stereoisomers thereof, characterised in that
 5 a compound of the formula II



in which R^1 , R^2 and R^3 have the meanings indicated in Claim 1,

is reacted with a compound of the formula III




in which

R^6 has the meanings indicated in Claim 1,

and

with a compound of the formula IV, the double-bond isomer (E isomer) thereof or mixtures thereof




in which R^4 and $R^{5'}$ have the meanings indicated in Claim 1,

and, if desired, a radical R^7 which denotes H is converted into a radical R^7 which has a meaning other than H,

and/or, if desired,


a base or acid of the formula I is converted into one of its salts.

9. Process according to Claim 8, characterised in that the reaction is carried out in the presence of a protonic acid or Lewis acid.
10. Process according to Claim 8 or 9, characterised in that the reaction is carried out in the presence of trifluoroacetic acid, hexafluoro-isopropanol, bismuth(III) chloride, ytterbium(III) triflate, scandium(III) triflate or cerium(IV) ammonium nitrate.
11. Medicament comprising at least one compound of the formula I according to Claim 1 to 7 and/or salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
12. Mixture comprise one or more compounds of the formula I and amount of one or more compounds of the formula V, analogues thereof and/or metabolites thereof



in which


Y' and Z' each, independently of one another, denote O or N, R⁹ and R¹⁰ each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, n denotes an integer between 2 and 6, each inclusive, and R⁸ and R¹¹ are each, independently of one another, in the meta- or para-position and are selected from the group:



13. Mixture according to Claim 12, where the compound of the formula V used is pentamidine or salts thereof.
14. Use of compounds according to Claim 1 to 7 and salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, or of the mixture according to Claim 12, for the preparation of a medicament for the treatment of diseases which can be influenced by the inhibition, regulation and/or modulation of the mitotic motor protein Eg5.
15. Use of compound according to Claim 1 to 7 or the mixture according to Claim 12 for the preparation of a medicament for the treatment and prophylaxis of cancer diseases.
16. Use according to Claim 15, where the cancer diseases are accompanied by a tumour from the group of tumours of the squamous epithelium, bladder, stomach, kidneys, head and neck, oesophagus, cervix,

thyroid, intestine, liver, brain, prostate, urogenital tract, lymphatic system, stomach, larynx and/or lung.

- 5 17. Use according to Claim 16, where the tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma.
- 10 18. Use according to Claim 15, where the cancer disease to be treated is a tumour of the blood and immune system.
- 15 19. Use according to Claim 18, where the tumour originates from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
- 20 20. Use of compounds of the formula I according to Claim 1 to 7 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of tumours in combination with a therapeutically effective amount of one or more compounds of the formula V, analogues thereof and/or metabolites thereof




30

in which

- Y' and Z' each, independently of one another, denote O or N, R⁹ and R¹⁰ each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, n denotes an integer between 2 and 6, each inclusive, and R⁸ and R¹¹ are each, independently of one another, in the meta- or para-position and are selected from the
- 35

group:



where

the compounds of the formula I and the compounds of the formula V, analogues thereof and/or metabolites thereof are administered simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of a tumour or of other hyperproliferative cells.

- 20 21. Use according to Claim 20, where the compound of the formula V used is pentamidine or salts thereof.
- 25 22. Use of compounds of the formula I according to Claim 1 to 7 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of tumours where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) anti-proliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.
- 30
- 35